

FY2009 FINANCIAL RESULTS

(April 1, 2009 - March 31, 2010)

Supplementary Information

May 12, 2010

<Contact>

Miraca Holdings Inc.

IR Public Relations Group

Phone: +81-3-5909-3337 Fax: +81-3-5909-3336

URL: <http://www.miraca-holdings.co.jp/>





Disclaimer regarding forward-looking statement:

The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncertainties. Please be aware that the actual performance may turn out to be different from the forecast as a result of various contributing factors.

Factors affecting the performance include, among others, aggravation of the economic situation, fluctuation of the exchange rate, change of regulatory, statutory, and administrative requirements, delayed launch of new products, pressures from the product strategies of competitive companies, and decline of the sales potential of existing products.

Consolidated Financial Highlights

	FY2005	FY2006	FY2007	FY2008	FY2009	Y/Y Variance (%)	FY2010 Forecast
<Key Items of Statement of Income>							
Net sales (millions of yen)	138,357	137,208	143,299	145,340	149,074	+2.6%	161,700
Operating income (millions of yen)	13,283	14,523	14,795	14,932	19,809	+32.7%	20,200
Ordinary income (millions of yen)	13,671	15,044	15,456	15,712	20,187	+28.5%	20,500
Net income (millions of yen)	8,064	8,447	8,297	8,709	11,587	+33.1%	11,600
Net income per share (yen)	135.91	140.40	137.61	148.64	199.06	—	199.27
Net income per share (diluted) (yen)	133.73	140.07	137.42	—	199.03	—	—
<Key Items of Balance Sheet>							
Total assets (millions of yen)	122,894	122,034	128,575	124,237	137,089	—	—
Net assets (millions of yen)	75,428	82,762	86,027	87,243	95,362	—	—
Net assets per share (yen)	1,260.64	1,361.65	1,430.46	1,491.14	1,633.58	—	—
<Key Indicators, etc.>							
Dividend payout ratio (%)	20.6	22.8	32.0	35.0	30.1	—	31.1
Return on equity (%)	13.0	10.7	9.9	10.1	12.7	—	—
Return on asset (%)	11.2	12.3	12.3	12.4	15.5	—	—
Equity ratio (%)	61.4	67.3	66.6	69.9	69.4	—	—
Number of consolidated subsidiaries	25	19	20	19	17	—	—



Notes:

* Each fiscal period is as follows;

FY2005 is a one-year period ending on March 31, 2006.

FY2006 is a one-year period ending on March 31, 2007.

FY2007 is a one-year period ending on March 31, 2008.

FY2008 is a one-year period ending on March 31, 2009.

FY2009 is a one-year period ending on March 31, 2010.

FY2010 is a one-year period ending on March 31, 2011.

* Figures are rounded to the appropriate unit in principle.

Consolidated Balance Sheets

<ASSETS>

(Millions of yen)

	End of FY2008 (Mar. 31, 2009)	End of FY2009 (Mar. 31, 2010)
<Assets>		
Current assets		
Cash and cash equivalents	14,555	15,601
Accounts and notes receivables	26,245	25,911
Lease investment assets	223	608
Marketable securities	13,000	23,899
Merchandise and finished goods	4,266	4,998
Work in process	3,655	3,948
Raw materials and supplies	3,565	3,243
Deferred tax assets - current	2,416	3,182
Other current assets	1,796	3,909
Allowance for doubtful receivables	-106	-45
Total current assets	69,619	85,258
Fixed assets		
Property, plant and equipment		
Buildings and structures, net	12,862	11,969
Machinery and equipment, net	1,542	1,560
Furniture and fixtures, net	7,534	7,158
Land	7,650	7,649
Lease assets, net	453	852
Construction in progress	678	820
Total property, plant and equipment	30,722	30,010
Intangible fixed assets		
Goodwill	3,566	4,685
Lease assets	14	16
Software	7,859	6,009
Other intangible fixed assets	2,066	1,856
Total intangible fixed assets	13,506	12,568
Investment and other assets		
Investment securities	2,463	1,751
Deferred tax assets - non-current	3,489	3,680
Other investments and other assets	4,543	3,852
Allowance for doubtful receivables	-107	-32
Total investments and other assets	10,389	9,251
Total fixed assets	54,618	51,830
Total assets	124,237	137,089

Notes: Figures are rounded down to the nearest million yen.

- ① Increase in marketable securities is mainly due to increase of negotiable certificate of deposit.
 ② Increase in goodwill is mainly due to the acquisition of all remaining shares of Care'x Inc..

Consolidated Balance Sheets

<LIABILITIES AND NET ASSETS>

(Millions of yen)

	End of FY2008 (Mar. 31, 2009)	End of FY2009 (Mar. 31, 2010)
<Liabilities>		
Current liabilities		
Accounts and notes payables	9,802	9,471
Short-term loans payables	1,593	2,001
Lease obligations	99	337
Accounts payable - others	4,820	5,480
Income taxes payable	2,273	5,301 ←①
Accrued bonuses	3,774	4,242
Other current liabilities	3,766	5,011
Total current liabilities	26,130	31,847
Long-term liabilities		
Long-term loans payables	204	252
Lease obligations	392	592
Deferred tax liabilities	222	256
Allowance for retirement benefits	6,831	5,249 ←②
Allowance for retirement benefits for directors and corporate auditors	—	25
Other long-term liabilities	3,212	3,503
Total long-term liabilities	10,864	9,879
Total liabilities	36,994	41,726
<Net assets>		
Owners' equity		
Capital stock	7,663	7,666
Capital surplus	23,385	23,388
Retained earnings	57,346	65,732
Treasury stock, at cost	-485	-491
Total owners' equity	87,909	96,294
Valuation and translation adjustments		
Unrealized gain on available-for-sale securities	25	62
Foreign currency translation adjustments	-1,134	-1,264
Total valuation and translation adjustments	-1,108	-1,202
Subscription rights to shares	192	270
Minority interests	249	—
Total net assets	87,243	95,362
Total liabilities and net assets	124,237	137,089

Notes: Figures are rounded down to the nearest million yen.

① Increase in income taxes payable is mainly due to increase of taxable income.

② Decrease in allowance for retirement benefits is mainly due to change in pension plan at Fujirebio.

Consolidated Statement of Income

(Millions of yen)

	FY2008 (April 1, 2008 - March 31, 2009)	FY2009 (April 1, 2009 - March 31, 2010)	YoY Variance	
Net sales	145,340	149,074	3,733	2.6%
Cost of sales	94,359	93,434	-925	-1.0%
Gross profit	50,981	55,640	4,658	9.1%
Selling, general and administrative expenses	36,049	35,831	-217	-0.6%
Operating income	14,932	19,809	4,876	32.7%
Non-operating income	1,039	537	-502	-48.3%
Interest received	49	22		
Dividends received	307	27		
Dividends income of insurance	—	120		
Equity in net gains of associated companies	193	23		
Income from contracting business	103	68		
Other non-operating income	385	274		
Non-operating expenses	259	158	-100	-38.8%
Interest expenses	42	24		
Rent expenses	45	43		
Foreign exchange losses	31	25		
Loss on investments in partnership	—	19		
Other non-operating expenses	139	45		
Ordinary income	15,712	20,187	4,475	28.5%
Extraordinary gains	140	359	219	155.9%
Gain on sales of fixed assets	10	4		
Gain on sales of investment securities	108	—		
Reversal of allowance for doubtful receivables	21	—		
Gain on revision of retirement benefits plan	—	342		
Other extraordinary gains	—	12		
Extraordinary loss	1,082	1,211	128	11.8%
Loss on disposals of fixed assets	407	448		
Loss on sales of fixed assets	3	0		
Loss on sales of investment securities	368	—		
Loss on devaluation of investment securities	256	32		
Impairment of fixed assets	—	217		
loss on recall of goods	—	420		
Other extraordinary losses	47	91		
Income before income taxes and minority interests	14,770	19,336	4,566	30.9%
Income taxes and enterprise taxes	5,105	8,722		
Income taxes adjustments	914	-985		
Total income taxes	6,020	7,736	1,716	28.5%
Minority interests	41	11	-29	-71.0%
Net income	8,709	11,587	2,878	33.1%

Notes: Figures are rounded down to the nearest million yen.

- ① Increase in net sales is mainly due to increase in sales of influenza test kits in *In Vitro Diagnostics* and effect of the consolidation of Care'x Inc. as a wholly owned subsidiary
- ② Increase in operating income is mainly due to profitability enhanced led by sales increase of influenza test kits and change in product structure in *In Vitro Diagnostics* and effect of reduction in fixed costs in *Clinical Lab Testing*.

Segment Results-1 (Consolidated)

<Performance by Business Segment>

(Millions of yen)

	FY2007	FY2008	FY2009	Y/Y Variance (%)	FY2010 Forecast
Net sales	143,299	145,340	149,074	+2.6%	161,700
In Vitro Diagnostics	32,730	32,331	32,892	+1.7%	32,300
Clinical Lab Testing	90,208	91,108	91,903	+0.9%	103,000
Others	20,359	21,901	24,278	+10.9%	26,400
Clinical Trials	5,444	5,670	5,843	+3.1%	—
Sterilizing	9,970	11,469	12,127	+5.7%	—
Preventive Medicine Related	4,944	4,760	6,306	+32.5%	—
Operating income	14,795	14,932	19,809	+32.7%	20,200
In Vitro Diagnostics	7,174	5,812	8,021	+38.0%	7,150
Clinical Lab Testing	5,670	6,866	9,265	+34.9%	10,450
Others	2,018	2,078	2,499	+20.3%	2,600
Clinical Trials	443	558	735	+31.7%	—
Sterilizing	812	891	900	+1.0%	—
Preventive Medicine Related	761	627	864	+37.8%	—
Elimination/corporate	-67	174	23	—	—

Notes: Figures are rounded down to the nearest million yen.

Segment Information (Consolidated)

(1) In Vitro Diagnostics Business

<Net Sales by Products Category>

(Billions of yen)

	FY2007	FY2008	FY2009
In Vitro Diagnostics	32.7	32.3	32.9
In-house products (own brand and finished products)	25.4	25.7	25.0
CL	12.5	16.2	15.3
HA·PA	6.8	3.7	3.3
EL	1.6	1.0	2.4
RI	1.1	1.1	1.0
Others	3.3	3.6	3.0
OEM, raw materials, partly-finished products, and license	7.4	6.7	7.9

Notes: Figures above are rounded to the nearest 100 million yen.

<Net Sales by Product Type>

(Billions of yen)

	FY2007	FY2008	FY2009
In Vitro Diagnostics	32.7	32.3	32.9
Reagent	27.2	26.6	28.3
Testing Instrument	3.0	3.3	1.8
Others	2.5	2.4	2.8

Notes: Figures above are rounded to the nearest 100 million yen.

<Net Sales by Sale Destination>

(Billions of yen)

	FY2007	FY2008	FY2009
In Vitro Diagnostics	32.7	32.3	32.9
Overseas	7.8	7.7	8.1
Americas	3.9	3.9	4.1
Europe	2.7	2.6	2.9
Asia/Pacific	1.2	1.2	1.1
Japan	25.0	24.6	24.8

Notes: Figures above are rounded to the nearest 100 million yen.

<JPY/USD Exchange Rate during the Period>

	FY2007	FY2008	FY2009
JPY/USD	114.31	100.56	92.86

Segment Information (Consolidated)

(2) Clinical Lab Testing Business

<Net Sales by Business Category>

(Billions of yen)

	FY2007	FY2008	FY2009
Clinical Lab Testing	90.2	91.1	91.9
Off-site Testing	74.1	74.4	73.6
FMS/Branch Lab	16.1	16.7	18.3

Notes: Figures above are rounded to the nearest 100 million yen.

<Net Sales by Testing Field>

	FY2007	FY2008	FY2009
Clinical Lab Testing	100%	100%	100%
Testing not covered by Medical service fee system by government	11.9%	12.1%	11.8%
General (urine, feces, etc.)	2.4%	2.4%	2.4%
Hematology	9.7%	10.2%	10.6%
Biochemistry I	17.6%	17.4%	17.2%
Biochemistry II	20.8%	20.7%	20.7%
Immunology	24.7%	24.3%	24.1%
Microbiology	6.9%	7.3%	7.0%
Pathology	4.0%	3.9%	3.7%
Others	2.0%	1.8%	2.4%

<Net Sales by Geographical Region in Japan>

	FY2007	FY2008	FY2009
Clinical Lab Testing	100%	100%	100%
Northern/eastern Japan			
Hokkaido Region	5.3%	5.0%	5.0%
Tohoku Region	6.4%	6.0%	5.9%
Kanto Region (incl. Tokyo and metropolitan area)	36.9%	36.5%	37.3%
Hokuriku Region	2.2%	2.2%	2.3%
Chubu Region	10.8%	11.1%	10.4%
Kinki Region (incl. Osaka)	12.0%	12.8%	13.3%
Southern/western Japan			
Chugoku and Shikoku Region	6.7%	6.8%	6.7%
Kjusyu Region	14.9%	14.8%	14.8%
Others (incl. clinical trial and outsourcing)	4.7%	4.6%	4.3%

Capital Expenditure (Consolidated)

<Research & Development Expenses>

(Millions of yen)

	FY2007	FY2008	FY2009	FY2010 (Forecast)
R&D Expenses	4,453	3,933	3,906	4,100
In Vitro Diagnostics	4,140	3,658	3,644	—
Clinical Lab Testing	312	274	256	—
Others	—	—	4	—
Miraca holdings	—	—	—	—

Notes: Figures are rounded down to the nearest million yen.

<Capital Expenditure>

(Millions of yen)

	FY2007	FY2008	FY2009	FY2010 (Forecast)
Capital Expenditure	12,351	6,027	6,906	9,200
In Vitro Diagnostics	2,112	1,965	1,944	—
Clinical Lab Testing	7,588	3,566	4,126	—
Others	198	412	815	—
Miraca holdings	2,451	83	19	—

Notes: Figures are rounded down to the nearest million yen.

The amount of capital expenditure includes cost of leasing testing instruments.

<Depreciation and Amortization>

(Millions of yen)

	FY2007	FY2008	FY2009	FY2010 (Forecast)
Depreciation & Amortization	9,222	10,545	9,086	10,400
In Vitro Diagnostics	2,468	2,519	2,285	—
Clinical Lab Testing	6,265	6,918	5,548	—
Others	300	313	516	—
Miraca holdings	187	793	735	—

Notes: Figures are rounded down to the nearest million yen.

The amount of amortization and depreciation includes cost of leasing testing instruments.

Employees (Consolidated)

<Number of Full-time Employees at End of Term>

	FY2007	FY2008	FY2009
Total	4,353	4,443	4,586
In Vitro Diagnostics	840	836	877
Clinical Lab Testing	2,637	2,613	2,594
Others	865	977	1,097
Clinical Trials	140	161	179
Sterilizing	610	706	759
Preventive Medicine Related	115	110	(*) 159
Miraca holdings	11	17	18

(*) Care'x is included in *Preventive Medicine Related* in FY2009.

Share of Stock

<Stock Information >

	End of Mar.2007	End of Mar.2008	End of Mar.2009	End of Mar.2010
Number of shares issued (thousands of share)	60,839	61,040	58,440	58,441
Number of shareholders	8,688	7,234	6,888	7,116
Share price (yen)	2,470	2,605	1,988	2,850
Aggregate market value of listed stock (billions of yen)	148.9	156.0	115.7	165.9

Notes: The number of issued shares includes treasury stocks.

Aggregated market value of listed stock is calculated on the basis of the number of shares excluding treasury stocks.
(Figures of aggregated market value of listed stock is rounded to the nearest 100 million yen)

<Treasury Stock>

	End of Mar.2007	End of Mar.2008	End of Mar.2009	End of Mar.2010
Number of treasury stocks	539,289	1,145,117	228,529	230,851

<Shareholder Distribution>

	End of Mar.2007	End of Mar.2008	End of Mar.2009	End of Mar.2010
Financial institutions in Japan	41.08	36.53%	34.35%	33.17%
Overseas investors	38.17	43.94%	47.98%	50.83%
Individuals and others in Japan	17.14	15.38%	15.08%	13.84%
Companies in Japan	1.91	1.87%	1.95%	1.24%
Securities companies in Japan	0.81	0.40%	0.25%	0.53%
Treasury stocks	0.89	1.88%	0.39%	0.39%

<Cash Dividends per Share>

(yen/share)

	FY2007	FY2008	FY2009	FY2010 (Forecast)
Interim dividends	22	26	29	31
Year-end dividends	22	26	(*) 31	31
Annual dividends per share	44	52	(*) 60	62

(*) The company decided to increase year-end dividends per share for FY2009 from 29 yen to 31 yen on May 11, 2010.
Therefore, annual dividends per share for FY2009 was increased to 60 yen.